News US biotech uses AI to pick antiviral for COVID-19 trial US biotech AI Therapeutics has begun a phase 2 trial of its LAM-002A, an antiviral drug that has shown promise against the SARS-CoV-2 coronavirus in the lab.
Patients Providing patient access to new therapies, with Dean Erhardt Dean Erhardt, founder of D2 Solutions, discusses patient access today versus the state of patient access tomorrow.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.